Ziconotide

In plain language

Ziconotide is a severe chronic pain drug, sold as Prialt, that is a synthetic copy of a poison from the fish-hunting cone snail. It is not a pill or a normal injection: it is delivered by a pump directly into the fluid around the spinal cord.

It blocks the specific channels nerve cells use to send pain signals, in a way that opioids do not, so it does not cause tolerance or breathing problems. But its psychiatric side effects (confusion, hallucinations) and the surgical pump it requires keep it a niche, last-resort medicine.

For students

Ziconotide is a synthetic omega-conotoxin MVIIA (25 residues, 3 disulfide bonds, about 2,639 Da) from Conus magus, discovered through Baldomero Olivera's venom peptide research at Utah. It selectively blocks N-type voltage-gated calcium channels (Cav2.2) on primary nociceptive afferents in the dorsal horn, preventing neurotransmitter release that carries pain signals.

Intrathecal delivery is mandated by its narrow therapeutic index systemically (hypotension via sympathetic blockade); three randomized placebo-controlled trials in severe chronic pain (n=457 combined across the pivotal program) showed significant visual analog scale pain reductions versus placebo. Onset of psychiatric adverse effects (confusion, hallucinations, paranoid reactions) is dose-related, requiring slow titration (initial 0.1 mcg/hr, no more than 2-3 increases per week), and the drug carries a warning against abrupt discontinuation (adverse event rebound). It is used in patients with refractory cancer pain or failed opioid therapy who already have or qualify for an intrathecal pump.

For researchers and instructors

Biochemistry. Conotoxin scaffolds (small, highly constrained, disulfide-rich) are the structural lesson: nature's solution to potency and selectivity in a 25-residue package, with six cysteines forcing a compact, protease-resistant fold.

Pharmacology. Intrathecal infusion starting at 0.1 mcg/hr with slow titration; systemic effects (hypotension, orthostatic hypotension) preclude IV use; psychiatric monitoring is mandatory; dose is capped at 19.2 mcg/hr in adults.

Human evidence. Three randomized placebo-controlled trials in severe chronic pain (one in cancer pain, one in AIDS pain, one in neuropathic pain) showed statistically significant pain reduction; clinical significance debate continues given the titration burden.

Teaching point. Teaches both the promise of venom-derived pharmacology (highly selective ion channel blockers) and the practical ceiling that delivery routes impose on otherwise elegant molecules.